Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
AssigneeNovartis AG
InventorsJohn David Rothermel, Horst F. Schran, Diane Greeley, TianLing Chen
Life of this patent
Estimating the term…
Abstract
Epothilone derivatives are co-administered with an antidiarrheal agent, e.g., a DPP-IV inhibitor, in the treatment of a proliferative disease.
Claims9
A combination which comprises (a) an antidiarrheal agent and (b) an epothilone derivative of formula I
- wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond,
- in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier;
- for simultaneous, separate or sequential use.
A method of preventing or controlling diarrhea associated with administering an epothilone derivative of formula I
- in which compound A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond, in free form or in the form of a pharmaceutically acceptable salt, to a patient, which comprises administering an effective amount of an antidiarrheal agent to the patient receiving treatment with the epothilone derivative.
A method for the treatment of a proliferative disease comprising administering an antidiarrheal agent in combination with an epothilone derivative of formula I
- in which compound A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond.
A commercial package comprising (a) an antidiarrheal agent and (b) an epothilone derivative of formula I
- wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond,
- together with instructions for simultaneous, separate or sequential use thereof in the treatment of a proliferative disease.
A combined preparation, which comprises (a) one or more unit dosage forms of an antidiarrheal agent and (b) one or more unit dosage forms of an epothilone derivative of formula I
- in which compound A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond, in free form or in the form of a pharmaceutically acceptable salt.
Dependencies are inferred from the claim text.